Literature DB >> 10361134

Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling.

J M Ho1, B K Beattie, J A Squire, D A Frank, D L Barber.   

Abstract

To study constitutive Janus kinase signaling, chimeric proteins were generated between the pointed domain of the ets transcription factor TEL and the cytosolic tyrosine kinase Jak2. The effects of these proteins on interleukin-3 (IL-3)-dependent proliferation of the hematopoietic cell line, Ba/F3, were studied. Fusion of TEL to the functional kinase (JH1) domain of Jak2 resulted in conversion of Ba/F3 cells to factor-independence. Importantly, fusion of TEL to the Jak2 pseudokinase (JH2) domain or a kinase-inactive Jak2 JH1 domain had no effect on IL-3-dependent proliferation of Ba/F3 cells. Active TEL-Jak2 constructs (consisting of either Jak2 JH1 or Jak2 JH2+JH1 domain fusions) were constitutively tyrosine-phosphorylated but did not affect phosphorylation of endogeneous Jak1, Jak2, or Jak3. TEL-Jak2 activation resulted in the constitutive tyrosine phosphorylation of Stat1, Stat3, and Stat5 as determined by detection of phosphorylation using activation-specific antibodies and by binding of each protein to a preferential GAS sequence in electrophoretic mobility shift assays. Elucidation of signaling events downstream of TEL-Jak2 activation may provide insight into the mechanism of leukemogenesis mediated by this oncogenic fusion protein.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10361134

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

Review 1.  Jaks and stats as therapeutic targets.

Authors:  J J O'Shea; R Visconti; T P Cheng; M Gadina
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 2.  Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Jorge Cortes; Srdan Verstovsek
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

3.  Signal transducer and activator of transcription 5b (Stat5b) serine 193 is a novel cytokine-induced phospho-regulatory site that is constitutively activated in primary hematopoietic malignancies.

Authors:  Abhisek Mitra; Jeremy A Ross; Georgialina Rodriguez; Zsuzsanna S Nagy; Harry L Wilson; Robert A Kirken
Journal:  J Biol Chem       Date:  2012-03-22       Impact factor: 5.157

4.  Modeling ETV6-JAK2-induced leukemia: insights from the zebrafish.

Authors:  Jurg Schwaller
Journal:  Haematologica       Date:  2012-12       Impact factor: 9.941

5.  Alternative TEL-JAK2 fusions associated with T-cell acute lymphoblastic leukemia and atypical chronic myelogenous leukemia dissected in zebrafish.

Authors:  Sara M N Onnebo; Parisa Rasighaemi; Janani Kumar; Clifford Liongue; Alister C Ward
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

6.  Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation.

Authors:  J Frantsve; J Schwaller; D W Sternberg; J Kutok; D G Gilliland
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

Review 7.  STAT signaling in the pathogenesis and treatment of cancer.

Authors:  D A Frank
Journal:  Mol Med       Date:  1999-07       Impact factor: 6.354

8.  Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements.

Authors:  Andrew Chase; Catherine Bryant; Joannah Score; Claudia Haferlach; Vera Grossmann; Juliana Schwaab; Wolf-Karsten Hofmann; Andreas Reiter; Nicholas C P Cross
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

9.  Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo.

Authors:  J A Kennedy; F Barabé; B J Patterson; J Bayani; J A Squire; D L Barber; J E Dick
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-31       Impact factor: 11.205

10.  Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia.

Authors:  Andrea Hoelbl; Christian Schuster; Boris Kovacic; Bingmei Zhu; Mark Wickre; Maria A Hoelzl; Sabine Fajmann; Florian Grebien; Wolfgang Warsch; Gabriele Stengl; Lothar Hennighausen; Valeria Poli; Hartmut Beug; Richard Moriggl; Veronika Sexl
Journal:  EMBO Mol Med       Date:  2010-03       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.